GSK Director Wendy Becker Increases Stake with Share Purchase

GlaxoSmithKline ( (GB:GSK) ) has issued an announcement.

GSK plc disclosed that independent non-executive director Wendy Becker purchased 3,334 ordinary shares in the company on 20 February 2026. The transaction was executed on the London Stock Exchange at a price of £22.1926 per share and represents a standard director dealing disclosure under market regulations.

This director share purchase signals personal financial commitment by a board member and may be viewed by investors as a vote of confidence in GSK’s prospects. The disclosure also underscores the company’s adherence to transparency and regulatory requirements around dealings by persons discharging managerial responsibilities.

The most recent analyst rating on (GB:GSK) stock is a Sell with a £19.00 price target. To see the full list of analyst forecasts on GlaxoSmithKline stock, see the GB:GSK Stock Forecast page.

Spark’s Take on GB:GSK Stock

According to Spark, TipRanks’ AI Analyst, GB:GSK is a Neutral.

The score is driven primarily by strong profitability and improving recent fundamentals, supported by constructive 2026 guidance and pipeline momentum. Valuation is reasonable with a modest yield, while the main constraint is technical overbought risk and ongoing balance-sheet/earnings-consistency considerations.

To see Spark’s full report on GB:GSK stock, click here.

More about GlaxoSmithKline

GSK plc is a global biopharma company focused on uniting science, technology and talent to develop medicines and vaccines that help people get ahead of disease. The company operates internationally with a broad portfolio targeting major therapeutic areas and public health needs, positioning it as a key player in the global pharmaceuticals and healthcare market.

Average Trading Volume: 8,824,146

Technical Sentiment Signal: Buy

Current Market Cap: £91.5B

For detailed information about GSK stock, go to TipRanks’ Stock Analysis page.